Economic evaluations of treatments for systemic fungal infections: A systematic review of the literature

PharmacoEconomics

Volumn 22, Issue 7, 2004, Pages 421-433

  Dixon, Simon ^a   McKeen, Emma ^b   Tabberer, Margaret ^b   Paisley, Suzy ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CIPROFLOXACIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; NYSTATIN; OFLOXACIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DRUG COST; DRUG INDUCED DISEASE; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FUNGAL MENINGITIS; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL DECISION MAKING; MORTALITY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REVIEW; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; MYCOSES; TREATMENT OUTCOME;

EID: 2942522861     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422070-00002     Document Type: Review

References (39)

1. Beck Sague CM, Jarvis WR. Secular trends in the epidemiology of noscomial fungal infections in the United States, 1980-1990. National Noscomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51
2. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-32
3. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-controlled study. Arch Intern Med 1989; 149: 2349-53
4. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275: 189-93
5. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29 (5): 1164-70
6. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86S-9S
7. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998; 36: 1886-9
8. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44
9. Fraser DW, Ward J, Ajello L, et al. Aspergillosis and other systemic mycoses: the growing problem. JAMA 1979; 242: 1631-5
10. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32
11. Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-8
12. Wilson L, Reyes C, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34
13. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8
14. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524-8
15. NHS Centre for Reviews and Dissemination. Making cost-effectiveness information accessible: the NHS Economic Evaluation Database Project: CRD guidance for reporting critical summaries of economic evaluations. (CRD reports; no.6) York: NHS CRD, 1996
16. Drummond M, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. London: Oxford University Press, 1997
17. Drummond M, Jefferson T, on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
18. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992; 30: 231-43
19. Buxton MJ, Dubois DJ, Turner RR, et al. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis: comparison of fluconazole and amphotericin B-based therapies. J Infect 1991; 23: 17-31
20. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476-83
21. Dranitsaris G, Phillips P, Rotstein C, et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics 1998; 13 (5): 509-18
22. Flynn TN, Kelsey SM, Hazel DL, et al. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy: treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 1999; 16 (5 Pt 2): 543-50
23. Krupova Y, Novotny J, Sabo A, et al. Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study. Int J Antimicrob Agents 1998; 10: 313-6
24. Manfredi R, Mastroianni A, Coronado OV, et al. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997; 157: 64-9
25. Persson U, Tennvall GR, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992; 2 (6): 500-8
26. Poirier JM, Hardy S, Isnard F, et al. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther Drug Monit 1997; 19: 525-9
27. Sajben P, Minarik T, Tomasik E, et al. Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study. Support Care Cancer 1993; 1: 214-6
28. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-41
29. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17: 373-81
30. Schroder CP, de Vries EG, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 1999; 43: 741-3
31. Skinner JL, Harris C, Aaron MF, et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J 2000; 46: 587-9
32. Tollemar J, Hockerstedt K, Ericzon BG, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo-controlled study. Transplantation 1995; 59: 45-50
33. Wakerly L, Craig AM, Malek M, et al. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. J Hosp Infect 1996; 33: 35-48
34. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 191-201
35. Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
36. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 501-13
37. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27
38. O'Brien B. Economic of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 1996; 34: DS99-DS108
39. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Int J Technol Assess Health Care 1996; 12: 698-713